Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Sage Therapeutics, Inc

Sage Therapeutics is a biopharmaceutical company focused on developing medicines for brain health disorders, particularly postpartum depression.

COM:SAGERX

Sage Therapeutics

Last Close

4.85

22/11 17:49

Market Cap

313.21M

Beta: -

Volume Today

333.42K

Avg: -

Financials Not Available